The expanding field of targeted treatment relies heavily on recombinant mediator technology, and a detailed understanding of individual profiles is essential for optimizing experimental design Recombinant Human Transferrin (HOLO) and therapeutic efficacy. Specifically, examining the characteristics of recombinant IL-1A, IL-1B, IL-2, and IL-3 reveal